HbA1c Variability and Cardiovascular Events in Patients with Prostate Cancer Receiving Androgen Deprivation Therapy

Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 71, 209, 10.3322/caac.21660 Mohler, 2019, Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology, J Natl Compr Canc Netw, 17, 479, 10.6004/jnccn.2019.0023 Mottet, 2021, EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent, Eur Urol, 79, 243, 10.1016/j.eururo.2020.09.042 Schaeffer, 2021, NCCN guidelines insights: prostate cancer, version 1.2021, J Natl Compr Canc Netw, 19, 134, 10.6004/jnccn.2021.0008 Hu, 2020, Cardiovascular effects of androgen deprivation therapy in prostate cancer, Arterioscler Thromb Vasc Biol, 40, e55, 10.1161/ATVBAHA.119.313046 Keating, 2006, Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer, J Clin Oncol, 24, 4448, 10.1200/JCO.2006.06.2497 Wang, 2016, Androgen deprivation therapy is associated with diabetes: evidence from meta-analysis, J Diabetes Investig, 7, 629, 10.1111/jdi.12472 Keating, 2014, Androgen deprivation therapy and diabetes control among diabetic men with prostate cancer, Eur Urol, 65, 816, 10.1016/j.eururo.2013.02.023 Haidar, 2009, Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes, Aging Male, 10, 189, 10.1080/13685530701653538 Bradley, 2018, Risk of diabetes complications among those with diabetes receiving androgen deprivation therapy for localized prostate cancer, Cancer Causes Control, 29, 785, 10.1007/s10552-018-1050-z Skriver, 2015, Relationship of HbA1c variability, absolute changes in HbA1c, and all-cause mortality in type 2 diabetes: a Danish population-based prospective observational study, BMJ Open Diabetes Res Care, 3, e000060, 10.1136/bmjdrc-2014-000060 Kim, 2021, Long-term HbA1c variability and the development and progression of diabetic retinopathy in subjects with type 2 diabetes, Sci Rep, 11, 4731, 10.1038/s41598-021-84150-8 Yang, 2020, Comparative predictive ability of visit-to-visit HbA1c variability measures for microvascular disease risk in type 2 diabetes, Cardiovasc Diabetol, 19, 105, 10.1186/s12933-020-01082-9 Lee, 2021, Glycemic and lipid variability for predicting complications and mortality in diabetes mellitus using machine learning, BMC Endocr Disord, 21, 94, 10.1186/s12902-021-00751-4 Lee, 2021, Predictions of diabetes complications and mortality using hba1c variability: a 10-year observational cohort study, Acta Diabetol, 58, 171, 10.1007/s00592-020-01605-6 Kong, 2015, Overview of the health care system in Hong Kong and its referential significance to mainland China, J Chin Med Assoc, 78, 569, 10.1016/j.jcma.2015.02.006 Tsoi, 2020, Epidemiology of gout in Hong Kong: a population-based study from 2006 to 2016, Arthritis Res Ther, 22, 204, 10.1186/s13075-020-02299-5 Tse, 2021, Relationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease, J Hypertens, 39, 1717, 10.1097/HJH.0000000000002866 Chan, 2022, Association between duration of gonadotrophin-releasing hormone agonist use and cardiovascular risks: a population-based competing-risk analysis, Prostate, 22, 204 Wai, 2022, Changes in emergency department visits, diagnostic groups, and 28-day mortality associated with the COVID-19 pandemic: a territory-wide, retrospective, cohort study, Ann Emerg Med, 79, 148, 10.1016/j.annemergmed.2021.09.424 Choi, 2015, Injury patterns and help-seeking behavior in Hong Kong male intimate partner violence victims, J Emerg Med, 49, 217, 10.1016/j.jemermed.2015.03.007 Chan, 2022, Cardiovascular outcomes and hospitalizations in Asian patients receiving immune checkpoint inhibitors: a population-based study, Curr Probl Cardiol, 48 Mulè, 2016, Average real variability of 24-h systolic blood pressure is associated with microalbuminuria in patients with primary hypertension, J Hum Hypertens, 30, 164, 10.1038/jhh.2015.66 Mena, 2005, A reliable index for the prognostic significance of blood pressure variability, J Hypertens, 23, 505, 10.1097/01.hjh.0000160205.81652.5a Ghouse, 2019, Visit-to-visit variability of hemoglobin A 1c in people without diabetes and risk of major adverse cardiovascular events and all-cause mortality, Diabetes Care, 42, 134, 10.2337/dc18-1396 Bancks, 2019, Fasting glucose variability in young adulthood and incident diabetes, cardiovascular disease and all-cause mortality, Diabetologia, 62, 1366, 10.1007/s00125-019-4901-6 Zhou, 2021, Fasting glucose variation predicts microvascular risk in ACCORD and VADT, J Clin Endocrinol Metab, 106, 1150, 10.1210/clinem/dgaa941 Akrivos, 2015, Glycemic control, inflammation, and cognitive function in older patients with type 2 diabetes, Int J Geriatr Psychiatry, 30, 1093, 10.1002/gps.4267 Chang, 2012, Acute and chronic fluctuations in blood glucose levels can increase oxidative stress in type 2 diabetes mellitus, Acta Diabetol, 49, S171, 10.1007/s00592-012-0398-x Golia, 2014, Inflammation and cardiovascular disease: from pathogenesis to therapeutic target, Curr Atheroscler Rep, 16, 435, 10.1007/s11883-014-0435-z Greten, 2019, Inflammation and cancer: triggers, mechanisms, and consequences, Immunity, 51, 27, 10.1016/j.immuni.2019.06.025 Cirne, 2021, The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer, Eur Heart J Cardiovasc Pharmacother, 8, 253, 10.1093/ehjcvp/pvab005 Lopes, 2021, Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial, Circulation, 144, 1295, 10.1161/CIRCULATIONAHA.121.056810